Somak Chatterjee

Birla Institute of Technology and Science, Pilani

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations”.

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3713

N/A

1.7DataRank · unranked

58 citations

Erin Larkins, Somak Chatterjee, Pallavi S. Mishra‐Kalyani, Stephanie Aungst, Emily Wearne +13 more

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2036

N/A

1.6DataRank · unranked

60 citations

Leigh Marcus, M. Naomi Horiba, Martha Donoghue, Somak Chatterjee, Pallavi S. Mishra‐Kalyani +12 more

FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3439

N/A

0.470DataRank · unranked

22 citations

Diana Bradford, Somak Chatterjee, Xiaoxue Li, Stephanie Aungst, Amy M. Skinner +22 more

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0873

N/A

0DataRank · unranked

48 citations

Amy Barone, Somak Chatterjee, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Emasenyie Isikwei +14 more